<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Buckley, Rita</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Law, Genevieve</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Thrombosis and Lymphoma Stalk Lupus Patients</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2012-12-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">23-24</style></pages><abstract><style  face="normal" font="default" size="100%">Patients with systemic lupus erythematosus (SLE) are at heightened risk of thrombosis [Mok CC et al. Arthritis Rheum 2005] and mortality [Cervera R et al. Medicine (Baltimore) 2003]. Additionally, women with SLE are also 2.05 to 2.27 times more likely to have a cerebral vascular accident)/myocardial infarction [Ward MM. Arthritis Rheum 1999 (Feb)]. This article discusses the use of hydroxychloroquine for the reduction of thrombosis in systemic lupus patients, and lymphoma risk in systemic lupus.</style></abstract><number><style face="normal" font="default" size="100%">19</style></number><volume><style face="normal" font="default" size="100%">12</style></volume></record></records></xml>